Genetic Technologies Limited Stock

Equities

GTG

AU000000GTG7

Healthcare Facilities & Services

Market Closed - Australian S.E. 01:39:41 2024-04-19 am EDT 5-day change 1st Jan Change
0.14 AUD -20.00% Intraday chart for Genetic Technologies Limited -20.00% +3.70%
Sales 2024 * - Sales 2025 * - Capitalization 16.16M 25.18M
Net income 2024 * -4M -6.23M Net income 2025 * - 0 EV / Sales 2024 * -
Net cash position 2024 * 2.9M 4.52M Net cash position 2025 * 2.5M 3.9M EV / Sales 2025 * -
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 88.17%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Genetic Technologies Limited

1 day-20.00%
1 week-20.00%
1 month+12.00%
3 months+27.27%
6 months-44.00%
Current year+3.70%
More quotes
1 week
0.13
Extreme 0.13
0.18
1 month
0.13
Extreme 0.125
0.19
Current year
0.09
Extreme 0.093
0.19
1 year
0.09
Extreme 0.093
0.40
3 years
0.09
Extreme 0.093
1.10
5 years
0.09
Extreme 0.093
1.40
10 years
0.09
Extreme 0.093
9.10
More quotes
Managers TitleAgeSince
Chief Executive Officer - 21-01-31
Chief Tech/Sci/R&D Officer - 15-12-31
Director/Board Member - 18-01-30
Members of the board TitleAgeSince
Director/Board Member 65 14-09-23
Chairman - 18-01-30
Director/Board Member - 18-01-30
More insiders
Date Price Change Volume
24-04-19 0.14 -20.00% 395,611
24-04-18 0.175 +2.94% 6,219
24-04-17 0.17 +3.03% 28
24-04-16 0.165 0.00% 63,460
24-04-15 0.165 -5.71% 11,148

Delayed Quote Australian S.E., April 19, 2024 at 01:39 am EDT

More quotes
Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor
More about the company

Annual profits - Rate of surprise